Business
Aytu BioScience to Report Fourth Quarter and Full Year Fiscal 2020 Results and Provide Business Update on Tuesday, October 6, 2020
Live Conference Call and Webcast at 4:30 PM ETENGLEWOOD, CO / ACCESSWIRE / October 5, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty
About this update from Aytu Biopharma, Inc.
[{"type":"text","content":"Live Conference Call and Webcast at 4:30 PM ETENGLEWOOD, CO / ACCESSWIRE / October 5, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the \"Company\"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the fiscal fourth quarter and year ended June 30, 2020 on October 6, 2020, at 4:30 p.m. ET. The Company will review accomplishments from the quarter and fiscal year and provide an overview of its business and growth strategy.The Company will file Form 10-K after the markets close on October 6, 2020.Conference Call Information1-877-407-9124 (toll-free)1-201-689-8584 (international)The webcast will be accessible live and archived at the following link, https://www.webcaster4.com/Webcast/Page/2142/37506 and on Aytu BioScience's website, within the Investors section under Events & Presentations, at aytubio.com, for 90 days.A replay of the call will be available for fourteen days. Access the replay by calling 1-877-481-4010 (toll-free) or 919-882-2331 (international) and using the replay access code 37506.About Aytu BioScience, Inc.Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or \"Low T\"), (ii) ZolpiMist®, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex® Sprinkle™, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu also distribute...